NASDAQ:SPRB

Spruce Biosciences - SPRB Stock Forecast, Price & News

$3.04

+0.03 (+1.00%)

(As of 02/2/2023 12:00 AM ET)

Add

Compare

Today's Range: $2.88
▼
$3.09
50-Day Range: $0.99
▼
$3.09
52-Week Range: $0.95
▼
$3.38

Volume: 195,470 shs
Average Volume: 3.97 million shs
Market Capitalization: $71.62 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.80

Institutional Ownership

Spruce Biosciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 196.1% Upside
$9.00 Price Target
Short Interest: Bearish
10.02% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.93
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.03) to ($1.92) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

316th out of 1,030 stocks

Pharmaceutical Preparations Industry

147th out of 502 stocks

3.4

Analyst's Opinion

Consensus Rating
Spruce Biosciences has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.00, Spruce Biosciences has a forecasted upside of 196.1% from its current price of $3.04.
Amount of Analyst Coverage
Spruce Biosciences has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
10.02% of the float of Spruce Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Spruce Biosciences has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Spruce Biosciences has recently increased by 77.13%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Spruce Biosciences does not currently pay a dividend.
Dividend Growth
Spruce Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SPRB.

3.8

News and Social Media Coverage

News Sentiment
Spruce Biosciences has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Spruce Biosciences this week, compared to 0 articles on an average week.
Search Interest
12 people have searched for SPRB on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.
MarketBeat Follows
8 people have added Spruce Biosciences to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Spruce Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.90% of the stock of Spruce Biosciences is held by insiders.
Percentage Held by Institutions
84.21% of the stock of Spruce Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Spruce Biosciences are expected to grow in the coming year, from ($2.03) to ($1.92) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Spruce Biosciences is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Spruce Biosciences is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Spruce Biosciences has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Spruce Biosciences (NASDAQ:SPRB) Stock

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

Receive SPRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SPRB Stock News Headlines

February 1, 2023 | finance.yahoo.com

Spruce Biosciences to Participate in the SVB Securities Global Biopharma Conference

January 31, 2023 | finance.yahoo.com

Spruce Biosciences, Inc. (SPRB) Now Trades Above Golden Cross: Time to Buy?

February 3, 2023 | Investor Place Media (Ad)

Cash Holders STILL Aren't Taking Steps to Prepare

Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.

January 10, 2023 | marketwatch.com

Thinking about buying stock in SWVL Holdings, Apexigen, Sonnet BioTherapeutics, Spruce Biosciences, or Tilray?

January 9, 2023 | msn.com

Peering Into Spruce Biosciences's Recent Short Interest

January 9, 2023 | markets.businessinsider.com

SVB Securities Reaffirms Their Hold Rating on Spruce Biosciences (SPRB)

January 9, 2023 | finance.yahoo.com

Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

January 6, 2023 | msn.com

December Jobs Report Showing Easing Wage Pressures Lift US Equity Futures

February 3, 2023 | Investor Place Media (Ad)

Cash Holders STILL Aren't Taking Steps to Prepare

January 6, 2023 | finance.yahoo.com

Spruce Biosciences Shares Skyrocket After Licensing Pact For Lead Program

January 5, 2023 | finance.yahoo.com

Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan

November 16, 2022 | finance.yahoo.com

JMP Says Forgotten Spruce Biosciences Could Draw Attention In 2023

November 10, 2022 | finance.yahoo.com

Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

October 26, 2022 | finance.yahoo.com

Spruce Biosciences to Participate in November Investor Conferences

September 30, 2022 | reuters.com

Spruce Biosciences Inc

September 14, 2022 | seekingalpha.com

SPRB Spruce Biosciences, Inc.

August 30, 2022 | finance.yahoo.com

Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

August 16, 2022 | seekingalpha.com

Spruce Biosciences (SPRB) Investor Presentation - Slideshow

August 10, 2022 | finance.yahoo.com

Spruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update

June 1, 2022 | finance.yahoo.com

Spruce Biosciences to Participate in June Investor Conferences

May 31, 2022 | finance.yahoo.com

Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference

May 11, 2022 | finance.yahoo.com

Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 3, 2022 | finance.yahoo.com

Spruce Biosciences to Participate in May Investor Conferences

April 11, 2022 | finance.yahoo.com

Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C., as Chief Regulatory and Quality Officer

March 16, 2022 | markets.businessinsider.com

Where Spruce Biosciences Stands With Analysts

March 14, 2022 | seekingalpha.com

Spruce Biosciences hires new Chief Medical Officer

March 14, 2022 | finance.yahoo.com

Spruce Biosciences Appoints Will Charlton, M.D., M.A.S., as Chief Medical Officer

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SPRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SPRB Company Calendar

Last Earnings: 11/10/2022
Today: 2/02/2023
Next Earnings (Estimated): 3/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SPRB
CUSIP: N/A
CIK: 1683553
Web: www.sprucebiosciences.com
Phone: 415-655-4168
Fax: N/A
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.00
High Stock Price Forecast: $20.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +123.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.88)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,290,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -46.64%
Return on Assets: -40.08%

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 7.76
Quick Ratio: 7.76

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.75 per share
Price / Book: 0.64

Miscellaneous

Outstanding Shares: 23,560,000
Free Float: 22,170,000
Market Cap: $71.62 million
Optionable: Not Optionable
Beta: 2.25

Key Executives

Mr. Michael G. Grey (Age 69)
Exec. Chairman
Comp: $65k

Mr. Samir M. Gharib CPA (Age 40)
CPA, M.B.A., Pres & CFO
Comp: $480k

Dr. Javier Szwarcberg M.D. (Age 52)
M.P.H., CEO & Director

Dr. Ralph William Charlton III (Age 52)
M.D., Chief Medical Officer

Dr. Libbie Mansell M.B.A.
Ph.D., Chief Regulatory & Quality Officer

Ms. P. J. Ramtin
Sr. VP of Bus. Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions

SPRB Stock - Frequently Asked Questions

Should I buy or sell Spruce Biosciences stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spruce Biosciences in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRB shares.
View SPRB analyst ratings or view top-rated stocks.
What is Spruce Biosciences' stock price forecast for 2023?: 6 Wall Street research analysts have issued 1-year price targets for Spruce Biosciences' stock. Their SPRB share price forecasts range from $3.00 to $20.00. On average, they anticipate the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 196.1% from the stock's current price.
View analysts price targets for SPRB or view top-rated stocks among Wall Street analysts.
How have SPRB shares performed in 2023?: Spruce Biosciences' stock was trading at $1.0974 at the start of the year. Since then, SPRB shares have increased by 177.0% and is now trading at $3.04.
View the best growth stocks for 2023 here.
Are investors shorting Spruce Biosciences?: Spruce Biosciences saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 1,210,000 shares, an increase of 77.1% from the December 31st total of 683,100 shares. Based on an average trading volume of 1,370,000 shares, the short-interest ratio is currently 0.9 days. Currently, 10.0% of the company's stock are sold short.
View Spruce Biosciences' Short Interest.
When is Spruce Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our SPRB earnings forecast.
How were Spruce Biosciences' earnings last quarter?: Spruce Biosciences, Inc. (NASDAQ:SPRB) posted its earnings results on Thursday, November, 10th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.06.

When did Spruce Biosciences IPO?: (SPRB) raised $75 million in an initial public offering on Friday, October 9th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets acted as the underwriters for the IPO.
What is Spruce Biosciences' stock symbol?: Spruce Biosciences trades on the NASDAQ under the ticker symbol "SPRB."
Who are Spruce Biosciences' major shareholders?: Spruce Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Marquette Asset Management LLC (0.29%). Insiders that own company stock include Bali Muralidhar, Camilla V Simpson, Holdings A/S Novo and Venture Fund Iii L Rivervest.
View institutional ownership trends.
How do I buy shares of Spruce Biosciences?: Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Spruce Biosciences' stock price today?: One share of SPRB stock can currently be purchased for approximately $3.04.
How much money does Spruce Biosciences make?: Spruce Biosciences (NASDAQ:SPRB) has a market capitalization of $71.62 million. The company earns $-42,290,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis.
How can I contact Spruce Biosciences?: The official website for the company is www.sprucebiosciences.com. The company can be reached via phone at 415-655-4168 or via email at investors@sprucebiosciences.com.

This page (NASDAQ:SPRB) was last updated on 2/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Spruce Biosciences - SPRB Stock Forecast, Price & News

Spruce Biosciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Spruce Biosciences (NASDAQ:SPRB) Stock

SPRB Stock News Headlines

SPRB Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SPRB Stock - Frequently Asked Questions

Overall MarketRank^™